Clinical Efficacy of Biosimilar Switch of Adalimumab for Management of Uveitis.

Simple item page
dc.contributor.authorMurray, G.M.
dc.contributor.authorGriffith, N.
dc.contributor.authorSinnappurajar, P.
dc.contributor.authorAl Julandani, D.A.
dc.contributor.authorClarke, S.L.N.
dc.contributor.authorHawley, D.P.
dc.contributor.authorChoi, J.
dc.contributor.authorGuly, C.M.
dc.contributor.authorRamanan, A.V.
dc.date.issued2024
dc.description.abstractBackground: Adalimumab has demonstrated efficacy in non-infectious uveitis. With the introduction of biosimilar agents such as Amgevita, we aimed to quantify efficacy and tolerability compared to Humira in a multi-centre UK cohort Methods: Patients identified from tertiary uveitis clinics in 3 centres, after institution-mandated switching was implemented. Results: Data collected for 102 patients, aged 2–75 years, with 185 active eyes. Following switch, rates of uveitis flare were not significantly different (13 events before, 21 after, p = .132). Rates of elevated intraocular pressure were decreased (32 before, 25 afterwards, p = .006) and dosing of oral and intra-ocular steroids was stable. Twenty-four patients (24%) requested to return to Humira, commonly due to pain from injection or technical difficulty with the device. Conclusion: Amgevita is safe and effective for inflammatory uveitis with non-inferiority to Humira. Significant numbers of patients requested to switch back due to side effects including injection site reactions.
dc.description.statementofresponsibilityG. M. Murray, N. Griffith, P. Sinnappurajar, D. A. Al Julandani, S. L. N. Clarke, D. P. Hawley, J. Choi, C. M. Guly, Athimalaipet V. Ramanan
dc.identifier.citationOcular Immunology and Inflammation, 2024; 32(4):442-446
dc.identifier.doi10.1080/09273948.2023.2172591
dc.identifier.issn0927-3948
dc.identifier.issn1744-5078
dc.identifier.orcidMurray, G.M. [0000-0003-0741-9288]
dc.identifier.urihttps://hdl.handle.net/2440/145029
dc.language.isoen
dc.publisherTaylor and Francis Group
dc.rights© 2023 The Author(s). This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
dc.source.urihttps://doi.org/10.1080/09273948.2023.2172591
dc.subjectAdalimumab; biosimilar; clinical efficacy; TNF-alpha; uveitis
dc.subject.meshHumans
dc.subject.meshUveitis
dc.subject.meshAnti-Inflammatory Agents
dc.subject.meshTreatment Outcome
dc.subject.meshRetrospective Studies
dc.subject.meshAdolescent
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshMiddle Aged
dc.subject.meshChild
dc.subject.meshChild, Preschool
dc.subject.meshFemale
dc.subject.meshMale
dc.subject.meshYoung Adult
dc.subject.meshDrug Substitution
dc.subject.meshBiosimilar Pharmaceuticals
dc.subject.meshAdalimumab
dc.titleClinical Efficacy of Biosimilar Switch of Adalimumab for Management of Uveitis.
dc.typeJournal article
pubs.publication-statusPublished

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
hdl_145029.pdf
Size:
318.52 KB
Format:
Adobe Portable Document Format
Description:
Published version
Download

Collections

Research Outputs